abemaciclib (verzenio) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Abemaciclib, previously known as LY2835219, is a potent and selective inhibitor of cyclin-dependent kinases: CDK4 and CDK6, developed by Eli Lilly, which is in clinical trial phase III for the treatment of breast cancer and non-small cell lung cancer (NSCLC) and in phase II for investigation of its treatment glioblastoma and melanoma.   NCATS

Chemistry

  • SMILES: CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C4=CC5=C(N=C(C)N5C(C)C)C(F)=C4)C=C2)CC1
  • InChIKey: UZWDCWONPYILKI-UHFFFAOYSA-N
  • Mol. Mass: 506.5934
  • ALogP: 4.94
  • ChEMBL Molecule:
    abemaciclib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$57.3444

United States

$151.5507 - $194.1336
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzimidazol-5-yl)pyrimidin-2-yl)amine | 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)pyrimidin-2-yl)amine | abemaciclib | ly2385219 | ly2835210 | ly2835219 | ly-2835219

Organizations (94)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (55)

Approved Indications (1)


 

Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Adenocarcinoma (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms ()

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Chondrosarcoma (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 1)

Endometrial Neoplasms (Phase 2)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fibrocystic Breast Disease (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Liposarcoma (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Melanoma (Phase 2)

Mesothelioma, Malignant (Phase 2)

Multiple Myeloma (Phase 2)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Neuroendocrine Tumors (Phase 2)

Neurofibromatosis 1 (Phase 1/Phase 2)

Oligodendroglioma (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Proto-Oncogene Proteins B-raf (Phase 2)

Rhabdoid Tumor (Phase 1)

Rhabdomyosarcoma (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 1)

Sarcoma, Kaposi (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 2)

Thyroid Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 134
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue